Tech Company Financing Transactions
RegCell Funding Round
RegCell, based in Emeryville, scored $45.8 million from Fast Track Initiative, UTEC and Kyoto University Innovation Capital (Kyoto iCAP).
Transaction Overview
Company Name
Announced On
3/18/2025
Transaction Type
Venture Equity
Amount
$45,800,000
Round
Undisclosed
Investors
Fast Track Initiative (Lead Investor)
UTEC (Lead Investor)
Proceeds Purpose
The company intends to use the funds for the development of its epigenetic reprogramming platform through clinical proof-of-concept to further validate the technology.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Emeryville, CA Undisclosed
USA
Emeryville, CA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
RegCell's goal is to fundamentally change the way we treat autoimmune diseases by offering therapies that don't simply address symptoms but provide function and balance to the immune system by restoring long-term immune tolerance in patients with autoimmunity. Our approach is based on the enormous body of work of our scientific founder, Dr. Shimon Sakaguchi.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael McCullar
Chief Financial Officer
James Ahlers
Chief Technical Officer
Marty Giedlin
Chief Technical Officer
Tony Hurley
Browse more venture capital transactions:
Prev: 3/18/2025: Cognition AI venture capital transaction
Next: 3/18/2025: Entegrata venture capital transaction
Share this article
News on VC Transactions
We do our best to document funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs